We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 328

Court finds claims do not cover method of medical treatment, orders that they issue

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 19 2015

In this decision, AbbVie brought a judicial review of a decision of the Commissioner of Patents refusing to issue its patent. The issue was whether

Minister’s decision to grant NOA to generic company set aside, as the generic did not comply with the NOC regulations

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 19 2015

In this proceeding, Pfizer sought to judicially review the Minister of Health’s decision to grant Teva a NOC for exemestane. A company called GMP

Court refused to grant protective order covering NOA

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 19 2015

In the context of a proceeding brought pursuant to the NOC Regulations, Mylan sought a confidentiality that would allow it to designate portions of

Bill C-43 signals forthcoming changes to the Canadian Patent Act

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 5 2015

On December 16, 2014, Bill C-43 received Royal Assent. The legislation includes amendments to the Canadian Patent Act that will eventually usher in

Doctrine of bona fide purchaser for value without notice applies to patent rights

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 6 2012

This case involves a dispute over who owned certain patent rights

Documents included in joint book for trial should be exhibits for appeal

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 11 2012

The issue to be determined relates to the contents of the appeal books

Claim to disgorgement of profits denied by Ontario Court of Appeal

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • September 18 2013

Apotex appealed in the Ontario Court of Appeal from a partial summary judgment that dismissed its unjust enrichment claim for the disgorgement of the

Antibody patent found valid and infringed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 27 2014

The Court recently decided a patent infringement case dealing with antibodies. The claims at issue in AbbVie’s patent relate to the use of a human

Reply affidavits allowed when new documents introduced in responding evidence

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 9 2014

In this case, there is a partial reversal of evidence. Apotex brought a motion for leave to file reply evidence. Allergan did not oppose parts of the

Appeal of refusal to add parties at remedy stage dismissed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 25 2012

The Court dismissed a motion for the joinder of parties at the remedy phase of an infringement action in which liability had been determined